Panacea Biotec AGM: All resolutions passed with over 99% majority
- All five resolutions at Panacea Biotec's 42nd AGM passed with requisite majority
- Adoption of FY26 financial statements received 99.9632% votes in favour
- Appointment of Rajinder Singh Manku as independent director approved as a special resolution
- Voting results filed with exchanges on October 1, 2026, pursuant to SEBI regulations
*this image is generated using AI for illustrative purposes only.
Panacea Biotec Limited announced on October 1, 2026, that all resolutions proposed at its 42nd Annual General Meeting (AGM) held on September 29, 2026, were passed with requisite majority. The company filed detailed voting results with stock exchanges pursuant to SEBI regulations.
Meeting proceedings and attendance
The meeting commenced at 11:30 am via video conferencing. Mr. Krishan Kumar Jalan, Independent Director, served as Chairman in the absence of Dr. Rajesh Jain. Key attendees included Joint Managing Director Sandeep Jain, Director Technical & Compliances Dr. Sanjay Trehan, and Group CFO Vinod Goel. Whole-time Directors Ankesh Jain and Harshet Jain were absent due to prior commitments.
Statutory Auditors Suresh Surana & Associates LLP and Secretarial Auditors R&D Company Secretaries attended virtually. The auditors' reports contained no qualifications or adverse remarks regarding the financial statements for the year ended March 31, 2026.
Resolutions transacted and voting results
Shareholders considered several items of business, categorized into ordinary and special business. The following table summarizes the voting outcomes based on total paid-up share capital:
| Business Type | Resolution | Status | Votes In Favour (%) |
|---|---|---|---|
| Ordinary | Adoption of audited standalone and consolidated financial statements for FY26 | Passed | 99.9632% |
| Ordinary | Re-appointment of retiring director Ankesh Jain | Passed | 99.9556% |
| Ordinary | Re-appointment of retiring director Harshet Jain | Passed | 99.9557% |
| Special | Appointment of Rajinder Singh Manku as independent director | Passed | 99.9614% |
| Ordinary | Ratification of remuneration for cost auditors Jain Sharma & Associates for FY27 | Passed | 99.9633% |
Remote e-voting was available from September 26 to September 28, 2026. Members who did not vote remotely could vote during the meeting. The Scrutinizer’s Report confirmed that all resolutions received overwhelming support from shareholders.
Shareholder queries and future outlook
During the question-and-answer session, shareholders raised queries regarding financial performance, vaccine development status, and regulatory approvals. Specific concerns included USFDA and EU GMP certifications for pharmaceutical formulation facilities and capacity enhancement for hexavalent vaccines. The management acknowledged these queries, stating that detailed replies would be provided in due course.
The company announced that voting results and the consolidated Scrutinizer's Report would be declared by October 1, 2026. These results have now been displayed on the company website, the National Securities Depository Limited website, and communicated to stock exchanges.
Historical Stock Returns for Panacea Biotec
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.90% | -5.95% | -9.22% | +21.28% | -11.76% | +25.59% |
When will Panacea Biotec release the detailed responses to shareholder queries regarding USFDA and EU GMP certifications?
How might the appointment of Rajinder Singh Manku as an independent director influence the company's governance strategy and regulatory compliance roadmap?
What are the projected timelines for the capacity enhancement of hexavalent vaccines, and how will this impact future revenue growth?
15
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
